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Gonorrhea,  one  of the  most  common  sexually  transmitted  infections  worldwide,  can  lead to  serious
sequelae,  including  infertility  and  increased  HIV  transmission.  Recently,  untreatable,  multidrug-resistant
Neisseria  gonorrhoeae  strains  have been  reported.  In  the absence  of new  antibiotics,  and  given  the  speed
with  which  resistance  has  emerged  to all  previously  used  antibiotics,  development  of  a vaccine  would
be  the  ideal  solution  to  this  public  health  emergency.  Understanding  the  desired  characteristics,  target
population,  and  expected  impact  of an  anti-gonococcal  vaccine  is essential  to  facilitate  vaccine  design,
assessment  and  implementation.  The  modeling  presented  herein  aims  to ﬁll  these  conceptual  gaps,  and
inform future  gonococcal  vaccine  development.  Using  an individual-based,  epidemiological  simulation
model,  gonococcal  prevalence  was  simulated  in  a  heterosexual  population  of 100,000  individuals  after
the introduction  of vaccines  with  varied  efﬁcacy  (10–100%)  and  duration  of  protection  (2.5–20 years).
Model  simulations  predict  that  gonococcal  prevalence  could  be reduced  by  at least  90% after  20  years,  if
all 13-year-olds  were  given  a  non-waning  vaccine  with  50%  efﬁcacy,  or a vaccine  with  100%  efﬁcacy  that
wanes  after  7.5  years.  A 40%  reduction  in  prevalence  is achievable  with  a non-waning  vaccine  of  only  20%
efﬁcacy.  We  conclude  that a  vaccine  of  moderate  efﬁcacy  and  duration  could  have  a substantive  impact
on  gonococcal  prevalence,  and  disease  sequelae,  if coverage  is  high  and  protection  lasts  over the  highest
risk  period  (i.e.,  most  sexual  partner  change)  among  young  people.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Neisseria gonorrhoeae, the causative agent of the sexually trans-
itted infection (STI) gonorrhea, is a growing global public health
roblem. The World Health Organization (WHO) estimates that,
orldwide, there are over 106 million new cases of gonorrhea
nnually [1]. However, incidence is expected to continue to rise
ith the increasing reports of treatment failures, particularly
ecause of increasing levels of untreatable multidrug-resistant N.
onorrhoeae strains [2]. The Centers for Disease Control (CDC)
ecently prioritized N. gonorrhoeae as one of three bacteria that
ose an “urgent” public health threat for which immediate aggres-
ive action is greatly needed. This is in large part because of the
apid increase in N. gonorrhoeae antibiotic resistance and, thus,
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the limited availability of effective therapeutics. Thereby, it is
anticipated that there will be an increase in the health and eco-
nomic burden of N. gonorrhoeae-related diseases [3].
The gonococcus has developed resistance to multiple classes of
antibiotics that have been used for treatment over the past decades,
including the penicillins, tetracyclines, macrolides, and quinolones.
Although ceftriaxone and ceﬁxime exist as the last remaining
options for empirical ﬁrst-line N. gonorrhoeae treatment, high-level
resistance (with treatment failure) to these expanded-spectrum
cephalosporins is now reported [2]. As a result, effective treatment
has become increasingly unaffordable, or non-existent, in those
communities with the highest burden of disease [4]. Although new
combination antibiotic treatments are being evaluated [5], there
are no alternative therapeutic options currently available, or in the
pipeline, for the treatment of gonococcal disease. Given the speed
at which N. gonorrhoeae develops resistance to newly introduced
antibiotics, it is also feared that even newly developed antibiotics
will only provide a short-term solution to control N. gonorrhoeae
[6]. In light of these issues, vaccination is considered the best
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
cine 33
l
d
n
c
e
i
s
i
o
c
b
o
t
a
o
c
f
g
t
a
o
i
t
a
o
[
e
l
o
t
n
a
l
i
f
c
s
c
c
w
o
t
t
r
t
t
v
2
f
t
t
c
h
c
c
c
t
g
o
p
1A.P. Craig et al. / Vac
ong-term approach for control of gonococcal disease. However,
espite continued research over the last century, there is currently
o gonococcal vaccine or vaccine candidates in advanced stages of
linical development [7]. In line with the CDC’s call for action, it is
ssential that gonococcal vaccine development be made a priority,
f we are to effectively combat this threat.
N. gonorrhoeae causes a range of clinical outcomes, including
evere sequelae. In men, gonococcal infection is typically character-
zed by a profusely symptomatic, localized inﬂammatory response
f the urethra (i.e., urethritis). A proportion of men  with gonococ-
al urethritis are asymptomatic (typically reported as 1–3% [8,9]
ut believed to be as high as 30–40% [10–12]), and complications
f untreated infection can include urethral stricture, urogenital
ract abscesses, prostatitis, and epididymo-orchitis [9]. The situ-
tion is more complicated and serious in women, with 50–80%
f lower genital tract N. gonorrhoeae infections (i.e., gonococcal
ervicitis) remaining asymptomatic [9,10,12]. Bacterial ascension
rom the cervix to the fallopian tubes occurs in up to 45% of
onococci-infected women, and can result in pelvic inﬂamma-
ory disease (PID: inﬂammation of the uterus, fallopian tubes,
nd/or ovaries) [13,14]. Other sequelae include adverse pregnancy
utcomes (pre-term birth, spontaneous abortion, stillbirth, low
nfant birth weight, ectopic pregnancy, chorioamnionitis, postpar-
um endometriosis or sepsis, ophthalmia neonatorum), infertility,
nd disseminated gonococcal infection [9]. Infection with N. gon-
rrhoeae also increases HIV replication, transmission, and infection
15–17]. In terms of economic burden, gonococcal infections are
stimated to account for annual medical costs exceeding $1.1 bil-
ion in the United States alone [18].
The WHO’s “Global Action Plan to Control the Spread and Impact
f Antimicrobial-Resistance in N. gonorrhoeae” [1] recommends
he use of mathematical modeling to analyze the feasibility of
ew interventions. To this end, we aimed to investigate various
spects (e.g., vaccine efﬁcacy, duration of protection, and coverage
evels) of potential gonococcal vaccines to estimate the possible
mpact on disease prevalence. Information obtained will help guide
uture vaccine development. For example, similar modeling of vac-
ines for Chlamydia trachomatis indicates that vaccine strategies
hould focus on women and that even partially effective vaccines
an greatly reduce the incidence of chlamydia [19]. Modifying the
hlamydia vaccine mathematical model to represent gonorrhea,
e simulated gonococcal transmission by considering the biology
f susceptible (non-infected) and infected individuals, as well as
heir sexual behaviors and partnership dynamics. This model tracks
hose parameters critical to gonococcal incidence and prevalence
ates and includes: duration and dynamics of infection and infec-
ivity, disease progression, and transmission rates. We  then used
his model to investigate the population-level impact of different
accine/vaccination scenarios.
. Materials and methods
We  adapted an established, individual-based model developed
or the study of Chlamydia vaccines [19] to explore N. gonorrhoeae
ransmission in populations, disease progression in individuals, and
he potential impact of various hypothetical vaccines with speciﬁed
haracteristics. This model represents the sexually-active, general
eterosexual population, and allows for both ongoing regular and
asual (short-term) partnerships. A section of the population is
onsidered to be a highly active “core group” and can have con-
urrent partnerships. We  used the same behavioral parameters as
hose previously applied to Chlamydia [19] (Table S1). In addition,
onorrhea-speciﬁc parameters (Table S2) were incorporated based
n reference to the literature, and by calibration, such that the mean
revalence of gonococcal infection in the absence of a vaccine was
.6–1.7% (based on the mean prevalence seen in different regions (2015) 4520–4525 4521
[20]). We  assumed that there is no immunity after the resolution of
an infection, which is in keeping with the high rates of reinfection
and the low levels of acquired immunity or immunological memory
following gonorrhea [21–24].
In our model, the per-exposure probability of transmitting gon-
orrhea depended on the gonococcal load of the infected partner
and followed the dynamics commonly seen in other bacterial and
viral infections. That is, initially, a low number of gonococci rapidly
reproduce until a peak level is reached, and bacterial numbers
then slowly decline to a low number at which point the infection
is considered resolved. The mathematical details of these in-host
dynamics are described previously [19]. We  adjusted the infectiv-
ity at peak gonococcal load (see Table S2; 0.5 (female to male)
and 1 (male to female)) to produce the expected prevalence in
the absence of a vaccine. Peak infectivity is attained only brieﬂy
in each infection; averaging over the full duration of infection, the
per-exposure probability of a woman infecting a man  was 0.28, and
the probability for a man  infecting a woman was  0.50. These prob-
abilities are comparable to those of 0.19–0.53 [25,26] (female to
male) and 0.5–0.65 [27,28] (male to female) noted in the literature.
We simulated vaccination programs in which vaccination takes
place at 13 years of age, assumed to be before sexual debut. Vaccines
were assumed to be prophylactic with constant efﬁcacy for the
duration stated, this being the relative chance the vaccine would
prevent any given transmission event. We  considered vaccines with
efﬁcacies of 10–100% and durations of 2.5–20 years; once the dura-
tion is exceeded, the individual would no longer be protected by
the vaccine. In that the possibility exists that a partially effective
vaccine could have the undesired side-effect of increasing the pro-
portion of infections that are asymptomatic (and, thereby, reduce
the proportion of infections that are treated), we also investigated
how this would affect prevalence.
First, we simulated an unvaccinated population of 100,000 indi-
viduals for 50 years to allow the sexual partnership, and the
gonococcal transmission dynamics to stabilize to equilibrium at a
population level (with individuals entering and exiting the popu-
lation over time). We  then simulated the vaccination of cohorts of
young people and how this would affect the dynamics of gonococ-
cal transmission in the population over 20 years. Ten simulations
were run for each vaccine/vaccination scenario, with the results
presented as the point-wise medians of the simulations’ trajecto-
ries.
As our model is individual-based, “stochastic extinction” some-
times occurs at very low prevalence levels. That is, at low
prevalence levels, random ﬂuctuations can result in the preva-
lence dropping to zero, whereas this would probably not happen
in a more realistically sized population of millions of people. Such
“stochastic extinction” was observed to happen when the preva-
lence level had fallen by over 90%. As such, even though some of
our simulations show extinction of gonorrhea from the population,
it is not possible to determine whether this would be seen in a real
population. In our results we  refer to such decreases in prevalence
as being greater than 90%, rather than 100%.
3. Results
If a gonorrhea vaccine with 100% efﬁcacy and 20 years duration
of protection becomes available, our simulation modeling analysis
predicts a more than 90% decrease in population prevalence within
15 years, provided all 13-year-olds are vaccinated (Fig. 1A). How-
ever, our simulations also indicated that even a partially efﬁcacious
vaccine would have a large effect on gonococcal prevalence in that
a vaccine of just 20% efﬁcacy could reduce gonorrhea prevalence by
approximately 40% after 20 years. The predicted prevalence under
this high coverage vaccination program, for vaccines ranging from
20 to 80% efﬁcacy, is shown in Fig. 1A.
4522 A.P. Craig et al. / Vaccine 33 (2015) 4520–4525
Fig. 1. The prevalence of gonorrhea in the absence of a vaccine, and with (A) vaccines
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if  differing efﬁcacies and 20 years duration of protection, or (B) vaccines with 100%
fﬁcacy and of differing durations of protection. Vaccine coverage is 100% of 13-
ear-olds.
A gonorrhea vaccine of short duration could also achieve a sub-
tantial impact on prevalence if it has a high protective efﬁcacy, is
mplemented with high coverage, and its duration is sufﬁcient to
rotect people during periods of high sexual mixing. In this regard,
e predicted that a vaccine of 7.5 years duration and 100% efﬁcacy
ould reduce prevalence by more than 90% in 20 years (Fig. 1B). A
accine of 5 years duration could halve prevalence after 20 years.
owever, even at 100% efﬁcacy, a vaccine with duration of only
.5 years would be expected to have a negligible impact on disease
revalence.
In practice, vaccine coverage may  not be universal. Nevertheless,
ur simulations suggested that the impact of a vaccine could be sub-
tantial even if a vaccination program achieved only 50% coverage
f the overall population. For example, the effect of vaccinating 50%
f 13-year-olds with a vaccine of 100% efﬁcacy and 20 years dura-
ion is expected to reduce prevalence by 90% after approximately
7 years (approximately ﬁve years longer than if 100% of 13-year-
lds were vaccinated) (Fig. 2A). If the vaccine efﬁcacy were 50%,
e would then expect 50% coverage of 13-year-olds to result in a
eduction in prevalence of approximately 50% of pre-vaccine levels
fter 20 years (Fig. 2B), as opposed to approximately 90% reduction
f coverage were 100%. Surprisingly, we found that the sex of those
accinated was unimportant as long as 50% of the eligible popula-
ion is vaccinated (Fig. 2A and B). However, policy makers might be
nterested in targeting vaccination at high-risk individuals, ratherFig. 2. The prevalence of gonorrhea in the absence of a vaccine, and with different
rates and types of vaccine coverage. (A) Vaccines have 100% efﬁcacy and 20 years
duration. (B) Vaccines have 50% efﬁcacy and 20 years duration.
than vaccinating the general population. Therefore, we simulated
vaccination of 25, 50 and 75% of incoming high-risk “core group”
individuals. With a vaccine of 100% efﬁcacy and 20 years dura-
tion, vaccinating 75% of incoming core group individuals is about
as effective, at a population level, as vaccinating 50% of all 13-year-
olds (Fig. S1A). With a vaccine of 50% efﬁcacy and 20 years duration,
vaccinating 75% of incoming core group individuals is marginally
more effective than vaccinating 50% of all 13-year-olds (Fig. S1B).
Given the difﬁculty of vaccine development for N. gonorrhoeae,
and the fact that the potential efﬁcacy and duration that a gon-
orrhea vaccine will have is unknown, we sought to calculate the
expected 20 year (Fig. 3A) and 10 year (Fig. 3B) prevalence rates
following vaccination of all 13-year-olds with vaccines of differ-
ing combinations of efﬁcacy and duration. The unshaded area in
Fig. 3A shows where the model estimated a reduction in preva-
lence of more than 90%. For example, our simulations indicated
that a vaccine of 20 years duration would be expected to reduce
gonococcal prevalence by more than 90% in 20 years, provided it
has an efﬁcacy greater than 50%. Whereas to obtain the same (90%)
reduction in disease prevalence, an efﬁcacy of 75% was necessary
for a vaccine with only 10 years duration. However, even a vac-
cine of 50% efﬁcacy and 10 years duration was expected to reduce
prevalence by approximately 50% after 20 years. It is also expected
that an impact would be seen after 10 years post-vaccination, with
prevalence reduced by more than 50%, for vaccines with efﬁcacy
greater than 70% and durations of at least 10 years (Fig. 3B).
A.P. Craig et al. / Vaccine 33
Fig. 3. The reduction in gonorrhea prevalence expected after (A) 20 years and (B)
10  years of vaccination. Simulations were run for combinations of efﬁcacy in 10%
increments and duration in 2.5 year increments, and curves were ﬁt to obtain the
smooth region boundaries. The reduction is relative to the prevalence in the no-
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naccine scenario after the given number of years. In panel B, vaccines with duration
f  ≥10 years are indistinguishable from one another because at that point in our
imulation model there has only been 10 years of vaccination.
It is conceivable that a partially protective vaccine could result
n a higher proportion of asymptomatic cases, resulting in a lower
roportion of cases being treated. We  found that a vaccine of
0% efﬁcacy and 20 years duration that caused all infections to
e asymptomatic would have a population-level impact virtually
nchanged from a similar vaccine that had no effect on symptoms
Fig. S2A). However, at lower efﬁcacies (e.g., 20%), the effect of a vac-
ine that caused all infections to be asymptomatic would be largely
ndistinguishable from the no-vaccine scenario (Fig. S2B).
. Discussion
In light of the rising incidence of N. gonorrhoeae [1], the sequelae
ssociated with infection, and the signiﬁcant level of antibiotic-
esistance that has emerged, there is an urgent need for the
evelopment of a gonococcal vaccine. The majority of vaccines
icensed to date target microorganisms that have little or no anti-
enic diversity and were developed using conventional vaccinology
pproaches (e.g., the use of inactivated or attenuated microbes),
hich aim to replicate the type of immunity seen after natural
nfection while removing the ability to cause disease [29]. However,
atural infection with N. gonorrhoeae does not provide immunity (2015) 4520–4525 4523
against reinfection [21–23], and attempts to develop a gonococ-
cal vaccine over the past century have proven unsuccessful, with
very few candidates progressing into clinical development [30,31].
This is largely because of a lack of knowledge as to what con-
stitutes a protective immune response against N. gonorrhoeae,
the heterogeneity and variability of gonococcal strains, and the
absence of robust animal models in which to study this obligate
human pathogen [30,32,33]. The feasibility of gonococcal vaccine
development is fueled by: (1) the recent increased need for a gono-
coccal vaccine because of treatment failures [2] and the consequent
potential change in the cost beneﬁt of a vaccine, (2) new vac-
cine technologies that enable engineering of antigens, optimization
of immune responses and target delivery [34], and (3) the suc-
cess of the vaccine against the STI, human papilloma virus (HPV)
[35]. Given the challenges encountered to date, it is unlikely that a
gonococcal vaccine will provide complete and life-long protection.
Therefore, a clear understanding of the level of protection required
to have a meaningful impact on N. gonorrhoeae prevalence at the
population level is needed. Here we used computational modeling
as a means to predict the impact of different vaccines and to bet-
ter guide decisions related to advancing vaccine targets into, and
through, clinical development.
In this study, we  adapted a model previously used for Chlamydia
[19] to simulate the transmission and prevalence of N. gonorrhoeae
associated with implementation of different hypothetical vaccines:
vaccines with different efﬁcacies (10–100%) and durations (2.5–20
years) when administered to different groups within the popu-
lation (e.g., 50–100% of either males, females, or both sexes over
the age of 13 years). We  found that gonorrhea vaccines with mod-
est efﬁcacies and durations of protection could have a substantive
impact on N. gonorrhoeae prevalence. A “perfect” vaccine with 100%
efﬁcacy and 20 years duration could reduce gonorrhea prevalence
by more than 90% in less than 15 years (Fig. 1). However, “imper-
fect”, or partially efﬁcacious, vaccines could also be valuable from
a public health perspective, with a 40% efﬁcacious vaccine with 20
years duration reducing prevalence by approximately 80% within
20 years. A vaccine of shorter duration (7.5 years) and 100% efﬁcacy
could achieve a similar impact. In this latter scenario, vaccination
would largely target, and thereby protect, the age group with the
highest rate of disease (i.e., 15–24 years) [36]. Importantly, we
would also expect reductions in infection incidence and preva-
lence to result in similar reductions in the incidence of PID and
other disease sequelae. This is of signiﬁcant importance as the CDC
has predicted that, if cephalosporin-resistant N. gonorrhoeae strains
become widespread, there would be an estimated additional 75,000
cases of PID, 15,000 cases of epididymitis, 222 HIV infections, and
over $200 million of direct medical costs in a 10-year period in the
USA alone [3].
Considering concerns about increasingly widespread, untreat-
able N. gonorrhoeae in the near future, it is important to note that
the impact of a gonococcal vaccine could be very fast. We  predicted
that a vaccine with 100% efﬁcacy and 20 years duration would
halve prevalence in just seven years (Figs. 1A and 3A), and even
a vaccine with >70% efﬁcacy and 10 years duration could halve
prevalence by 10 years (Fig. 3B). Indeed, it is previously noted that
gonorrhea responds very quickly to real-world interventions with
impacts seen in just months [37]. The effect of a vaccine on another
STI, HPV, has also been rapid; ﬁve years after its introduction in
Australia in 2007 there were 93% fewer diagnoses of genital warts
[35]. We found that, if vaccines with 100% or 50% efﬁcacy and 20
years duration were restricted to just half of 13-year-olds, it would
not matter whether they were females, males, or an even mix  of the
two sexes (Fig. 2). This is, again, consistent with experience with the
HPV vaccine, which lowered genital warts by 82% in males, despite
them being unvaccinated [35]. That the beneﬁts of a gonorrhea vac-
cine would extend across sexes is an important ﬁnding, as human
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hallenge trials maybe limited to males [38], and our results sug-
est that this would not substantially bias estimates of the vaccine’s
ffectiveness.
We found that targeting high-risk “core group” members was
ery effective; vaccinating 75% of incoming core group members
chieved a comparable population-level result to that determined
or vaccinating 50% of all 13-year-olds (Fig. S1). As the core group
s assumed to be just 5% of the population, targeting this group
ould require far less vaccinations to achieve a similar outcome
as is observed in other modeling studies [39]). However, a key
uestion for policy makers would be how easily the core group
an be accessed. In regions in which there is a high concentration
f gonorrhea cases among sex workers, and in which there exist
ood outreach programs for sex workers, we would expect target-
ng this population to be a particularly effective approach. However,
f core group members are more difﬁcult to identify, or to reach,
hen vaccinating the general population might be more efﬁcient.
This study provides ﬁndings that can help guide vaccine devel-
pment. We  provide vaccine characteristic targets for efﬁcacy and
uration of protection necessary for a vaccine to have an impact.
accine characteristics (as indicated in our simulations) required to
ield a population-level impact are in-line with currently licensed
accines proﬁles that have had substantial public health impacts.
or example, in terms of coverage, >70% of ∼12-year-old girls have
eceived 3 doses of the HPV vaccine in many countries, following
argeted national HPV immunization programs (e.g., in Australia)
40,41]. In terms of protective efﬁcacy and duration, whereas some
accines have estimated efﬁcacies of >90% and provide lifelong
rotection after a single dose (e.g., the rubella vaccine [42]), the
ajority of currently licensed and widely used vaccines have “less
ptimal” proﬁles in terms of their efﬁcacy, duration, and immu-
ization schedule. For example, BCG vaccination is estimated to
rovide 52% protection against tuberculosis for 10 years [43,44];
nd the DTP vaccine has 80–100% efﬁcacy with three doses being
equired in infancy to provide protection for 3–5 years against
etanus and with additional boosters needed throughout life [45].
t is also important to note that, like gonorrhea [22], recovery from
linical tetanus does not typically result in protection against the
isease in the future, yet the tetanus toxoid-based vaccines are
ighly effective at preventing disease [45].
There are some limitations to our analyses. First, we  have
ssumed an entirely heterosexual population. Men  who  have sex
ith men  (MSM) have an increased prevalence of gonorrhea
46,47]. Therefore, a vaccine might be expected to have an increased
mpact in these communities. Alternatively, the higher number of
artnerships, and consequent higher number of gonococcal chal-
enges, seen in this population could also mean that a gonorrhea
accine could be less effective than our simulations indicated for
he heterosexual population. This is an important subject for future
esearch. Whereas links between gonococcal load and transmis-
ibility are suggested [48], to our knowledge, this has not been
irectly investigated and prospective partner studies are needed
o conﬁrm this association. However, the load versus transmission
elationship has been investigated for human immunodeﬁciency
irus and HPV [49–51] and is featured in a more simpliﬁed form
n a model of trachoma (C. trachomatis) [52]. We  assumed that a
imilar relationship exists for N. gonorrhoeae. Second, we based
ur model on a vaccine that provides high strain coverage, which
s possible given the ongoing advances in antigen discovery and
ngineering and the likelihood that a gonococcal vaccine will con-
ain a combination of antigens. A vaccine that does not provide
rotection against all strains of N. gonorrhoeae would be expected
o reduce prevalence, as predicted in our results, for those strains
gainst which it is protective, while leaving the prevalence of other
trains unchanged. Finally, there are several aspects of gonococcal
nfection that we have not attempted to include in our model. We (2015) 4520–4525
did not attempt to estimate the gonococcal-related PID incidence
and potential cases averted due to vaccination. Our model also does
not take into account the confounding issue of the female genital
tract microbiome or co-infection with other STIs, both of which may
increase, or decrease, the rate of transmission and/or acquisition of
N. gonorrhoeae [53,54]. Moreover, we assumed that 66% of infected
women and 36% of infected men  are asymptomatic [12], but this
may  vary based on prevalence and screening methods used. Lastly,
our model assumes a prevalence of gonorrhea that is intermediate
in terms of levels reported for different WHO  regions worldwide
[20], and a vaccine may  have a different impact in higher or lower
prevalence settings. For the purposes of this study, we have chosen
to take a simpliﬁcation approach to these points, albeit they could
be explored, and expanded upon, in future modeling studies.
In summary, our mathematical simulation indicates that even
partially effective vaccines could have a signiﬁcant impact on the
prevalence of N. gonorrhoeae. These data, regarding the potential
ability of a N. gonorrhoeae vaccine to reduce the prevalence of infec-
tions, will provide a basis for future development, implementation,
and evaluation of candidate vaccines.
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